Core Insights - UCB's drug, Zilucoplan (brand name: Zhuobeike), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult generalized myasthenia gravis (GMG) patients who are positive for acetylcholine receptor (AChR) antibodies [1] - Zilucoplan is the first and only subcutaneous self-administered C5 complement inhibitor, which can effectively block complement-mediated neuromuscular junction damage, allowing patients to self-administer the injection at home in just 5-8 seconds [1] - The prevalence of generalized myasthenia gravis in China is approximately 220,000 patients, with AChR antibodies detected in 80%-90% of cases [1] Drug Market Overview - Several drugs for generalized myasthenia gravis have entered the Chinese market recently, including UCB's other drug, Rozanolixizumab (brand name: Yudige), which was approved in March and covers both AChR-positive and MuSK-positive patients [1] - AstraZeneca's long-acting C5 complement inhibitor, Riluzole (brand name: WeiliRui), was approved in April for AChR-positive adult GMG patients [2] - Rongchang Biotech's Taitasip (brand name: Tai'ai) was also approved in May for AChR-positive adult GMG patients [2] - The number of subcutaneous injection options remains limited compared to intravenous formulations, with the approval of Efgartigimod (brand name: WeiliJia) in July last year, which requires a longer administration time of 30-90 seconds [2]

新京报讯3月31日，国家药监局网站显示，罗泽利昔珠单抗注射液(商品名为优迪革)获得批准，与常规 治疗药物联合用于治疗乙酰胆碱受体(AChR)或肌肉特异性受体酪氨酸激酶(MuSK)抗体阳性的成人全身 型重症肌无力(gMG)患者。该药也是全球首个且唯一同时覆盖AChR阳性和MuSK阳性gMG的新生儿Fc 受体(FcRn)拮抗剂，此次获批填补了国内MuSK阳性患者靶向治疗的空白。 复旦大学附属华山医院神经内科主任医师、中国重症肌无力协作组组长赵重波教授指出，相较于其他罕 见病，重症肌无力的诊断相对明确，通过积极且规范的治疗，大多数患者的病情能够得到有效控制，但 病情控制住并不等同于生活质量的全面恢复。罗泽利昔珠单抗注射液获批上市，不仅填补了MuSK抗体 阳性患者靶向治疗的空白，也为重症肌无力患者提供了更具针对性的治疗选择，这对改善患者生活质量 及促进其回归正常生活具有重要意义。 重症肌无力是一种自身免疫性神经肌肉传递障碍罕见疾病，可引起明显的肌无力、疲劳等症状，导致言 语、行动、呼吸等身体功能受限，或合并胸腺瘤，疾病加重至肌无力危象(累及呼吸肌导致呼吸衰竭)可 危及生命。数据显示，我国重症肌无力年发病率为0.68/ ...